1. |
Le JY, Rhe CK, Jung KS, et al. Strategies for management of the early chronic obstructive lung disease. Tuberc Respir Dis (Seoul), 2016, 79(3): 121-126.
|
2. |
Yazici O, Gulen ST, Yenisey C, et al. Comparison of inflammation biomarkers among chronic obstructive pulmonary disease groups: a cross sectional study. Niger J Clin Pract, 2020, 23(6): 817-824.
|
3. |
顾金金, 刘强, 毛善奎. 阿托伐他汀对稳定期COPD患者肺功能、肺动脉压及相关指标影响的Meta分析. 中国药房, 2017, 28(33): 4682-4685.
|
4. |
王戈. 阿托伐他汀对烟熏慢性阻塞性肺病大鼠肺组织内质网应激和炎症的影响. 河北医药, 2019, 41(10): 1502-1505.
|
5. |
何永鸿, 强丽, 王宋平, 等. 阿托伐他汀钙对COPD模型大鼠肺血管重塑的影响及机制探讨. 天津医药, 2021, 49(6): 598-602.
|
6. |
Zhu B, Ma AQ, Yang L, et al. Atorvastatin attenuates bleomycin-induced pulmonary fibrosis via suppressing iNOS expression and the CTGF (CCN2)/ERK signaling pathway. Int J Mol Sci, 2013, 14(12): 24476-24491.
|
7. |
Eapen MS, Hansbro PM, McAlinden K, et al. Abnormal M1/M2 macrophage phenotype profiles in the small airway wall and lumen in smokers and chronic obstructive pulmonary disease (COPD). Sci Rep, 2017, 7(1): 13392.
|
8. |
王慧, 张鑫, 薛乾隆, 等. 膈肌呼出气一氧化氮浓度、一氧化氮合酶表达水平及炎性因子水平与食管病变并慢性阻塞性肺疾病患者膈肌活动度的相关性研究. 实用心脑肺血管病杂志, 2019, 27(11): 49-54.
|
9. |
Momeni B, Nazer S, Masoompour SM, et al. The effect of atorvastatin on inflammatory markers in sulfur mustard gas induced bronchitis: a randomized double-blinded, placebo-control clinical trial. BMC Pulm Med, 2021, 21(1): 112.
|
10. |
Arian A, Mortazavi Moghadam SG, Kazemi T, et al. Trial of atorvastatin on serum interleukin-6, total antioxidant capacity, C-reactive protein, and alpha-1 antitrypsin in patients with chronic obstructive pulmonary disease. J Res Pharm Pract, 2018, 7(3): 141-146.
|
11. |
Li HY, Su YY, Zhang YF, et al. Involvement of peroxisome proliferator activated receptor-gamma in the anti-inflammatory effects of atorvastatin in oxygen-glucose deprivation/reperfusion-stimulated RAW264.7 murine macrophages. Mol Med Rep, 2016, 14(5): 4055-4062.
|
12. |
Lisi F, Zelikin AN, Chandrawati R. Nitric oxide to fight viral infections. Adv Sci (Weinh), 2021, 8(7): 2003895.
|
13. |
Takatani Y, Ono K, Suzuki H, et al. Inducible nitric oxide synthase during the late phase of sepsis is associated with hypothermia and immune cell migration. Lab Invest, 2018, 98(5): 629-639.
|
14. |
Zhu XM, Wang Q, Xing WW, et al. PM2.5 induces autophagy-mediated cell death via NOS2 signaling in human bronchial epithelium cells. Int J Biol Sci, 2018, 14(5): 557-564.
|
15. |
白林林, 王志华, 宁学聪, 等. IL-17A对慢性阻塞性肺疾病的干预作用及其机制. 中国应用生理学杂志, 2021, 37(6): 5.
|
16. |
Knaut C, Bonfanti Mesquita C, Dourado VZ, et al. Evaluation of inflammatory markers in patients undergoing a short-term aerobic exercise program while hospitalized due to acute exacerbation of COPD. Int J Inflam, 2020, 2020: 6492720.
|
17. |
Sanja M, Jozsef P, Sanja PG, et al. Cytokines and statin therapy in chronic obstructive pulmonary disease patients. Scand J Clin Lab Invest, 2018, 78(7-8): 533-538.
|
18. |
David B, Bafadhel M, Koenderman L, et al. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax, 2021, 76(2): 188-195.
|
19. |
Prado CM, Righetti RF, Lopes FDTQDS, et al. iNOS inhibition reduces lung mechanical alterations and remodeling induced by particulate matter in mice. Pulm Med, 2019, 2019: 4781528.
|